RU2012153703A - Соединения двухцепочечных рнк к rhoa и их применение - Google Patents
Соединения двухцепочечных рнк к rhoa и их применение Download PDFInfo
- Publication number
- RU2012153703A RU2012153703A RU2012153703/10A RU2012153703A RU2012153703A RU 2012153703 A RU2012153703 A RU 2012153703A RU 2012153703/10 A RU2012153703/10 A RU 2012153703/10A RU 2012153703 A RU2012153703 A RU 2012153703A RU 2012153703 A RU2012153703 A RU 2012153703A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- rhoa
- molecule
- pharmaceutically acceptable
- damage
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims abstract 21
- 150000003839 salts Chemical class 0.000 claims abstract 16
- 230000000692 anti-sense effect Effects 0.000 claims abstract 15
- 108020004707 nucleic acids Proteins 0.000 claims abstract 15
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 15
- 102000039446 nucleic acids Human genes 0.000 claims abstract 15
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 14
- 239000002773 nucleotide Substances 0.000 claims abstract 10
- 230000014509 gene expression Effects 0.000 claims abstract 8
- 101150111584 RHOA gene Proteins 0.000 claims abstract 7
- 108091081021 Sense strand Proteins 0.000 claims abstract 5
- 108091033380 Coding strand Proteins 0.000 claims abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 31
- 201000010099 disease Diseases 0.000 claims 18
- 230000006378 damage Effects 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 13
- 108091028664 Ribonucleotide Proteins 0.000 claims 11
- 239000002336 ribonucleotide Substances 0.000 claims 11
- 208000016354 hearing loss disease Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 230000004770 neurodegeneration Effects 0.000 claims 7
- 206010011878 Deafness Diseases 0.000 claims 6
- 230000010370 hearing loss Effects 0.000 claims 6
- 231100000888 hearing loss Toxicity 0.000 claims 6
- 230000000302 ischemic effect Effects 0.000 claims 6
- 201000001119 neuropathy Diseases 0.000 claims 6
- 230000007823 neuropathy Effects 0.000 claims 6
- 230000003287 optical effect Effects 0.000 claims 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 206010053552 allodynia Diseases 0.000 claims 4
- 230000006931 brain damage Effects 0.000 claims 4
- 231100000874 brain damage Toxicity 0.000 claims 4
- 208000029028 brain injury Diseases 0.000 claims 4
- 239000005547 deoxyribonucleotide Substances 0.000 claims 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 201000006366 primary open angle glaucoma Diseases 0.000 claims 4
- 102100022387 Transforming protein RhoA Human genes 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 208000020431 spinal cord injury Diseases 0.000 claims 3
- 230000009529 traumatic brain injury Effects 0.000 claims 3
- HTXMJCHSFOPGME-UHFFFAOYSA-N 4,7-dimethoxy-1,3-benzodioxole Chemical compound COC1=CC=C(OC)C2=C1OCO2 HTXMJCHSFOPGME-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 241000533363 Apion Species 0.000 claims 2
- 208000006373 Bell palsy Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000027530 Meniere disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 241000920340 Pion Species 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 210000001328 optic nerve Anatomy 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000009424 thromboembolic effect Effects 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- 230000008736 traumatic injury Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 206010010071 Coma Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000003961 neuronal insult Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 101150079354 rho gene Proteins 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35801210P | 2010-06-24 | 2010-06-24 | |
| US61/358,012 | 2010-06-24 | ||
| PCT/US2011/041562 WO2011163436A1 (en) | 2010-06-24 | 2011-06-23 | Double stranded rna compounds to rhoa and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012153703A true RU2012153703A (ru) | 2014-07-27 |
Family
ID=44453954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012153703/10A RU2012153703A (ru) | 2010-06-24 | 2011-06-23 | Соединения двухцепочечных рнк к rhoa и их применение |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9045755B2 (enExample) |
| EP (1) | EP2585594B1 (enExample) |
| JP (1) | JP5824515B2 (enExample) |
| KR (1) | KR101553753B1 (enExample) |
| CN (1) | CN103097534B (enExample) |
| AU (1) | AU2011270896B9 (enExample) |
| CA (1) | CA2801928C (enExample) |
| IL (1) | IL223578A (enExample) |
| NZ (1) | NZ604094A (enExample) |
| RU (1) | RU2012153703A (enExample) |
| SG (1) | SG186438A1 (enExample) |
| WO (1) | WO2011163436A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2773758B1 (en) | 2011-11-03 | 2017-06-07 | Quark Pharmaceuticals, Inc. | Compositions for use in neuroprotection |
| WO2015023110A1 (ko) * | 2013-08-12 | 2015-02-19 | 사회복지법인 삼성생명공익재단 | 종양 질환 진단용 바이오마커 및 이의 용도 |
| JP6519927B2 (ja) * | 2013-09-06 | 2019-05-29 | 国立大学法人 東京大学 | 癌の診断、阻害剤のスクリーニングにおけるｒｈｏａの使用 |
| KR101754478B1 (ko) | 2015-08-06 | 2017-07-07 | 순천향대학교 산학협력단 | 위축성 질염 진단용 바이오 마커 조성물 및 이를 포함하는 진단키트 |
| JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
| CN108245528A (zh) * | 2018-02-01 | 2018-07-06 | 河南省立眼科医院（河南省眼科研究所） | 一种视神经保护的药物 |
| CN112315984B (zh) * | 2020-09-09 | 2023-02-14 | 山东省科学院生物研究所 | 海洋来源磷脂在促进血管生成方面的应用 |
| CN113887569B (zh) * | 2021-09-09 | 2022-10-25 | 同济大学 | 一种基于区域尺度的事故多发区域判别方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| CA2126691C (en) | 1991-12-24 | 2003-05-06 | Phillip Dan Cook | Gapped 2' modified oligonucleotides |
| CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
| WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| AU679566B2 (en) | 1993-09-03 | 1997-07-03 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| JPH10501686A (ja) | 1994-04-13 | 1998-02-17 | ザ ロックフェラー ユニヴァーシティ | 神経系の細胞へのｄｎａのａａｖ仲介送達 |
| US6447796B1 (en) | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| CA2207593A1 (en) | 1994-12-13 | 1996-06-20 | John Gustofson | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6235310B1 (en) | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| WO1999031262A2 (en) | 1997-12-16 | 1999-06-24 | Valentis, Inc. | Needle-free injection of formulated nucleic acid molecules |
| ES2356342T3 (es) | 1998-01-05 | 2011-04-07 | The University Of Washington | Mejora de transporte utilizando agentes de alteración de membrana. |
| DE69906977T2 (de) | 1998-07-20 | 2004-05-19 | Protiva Biotherapeutics Inc., Burnaby | In liposomen verkapselte nukleinsäurekomplexe |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| AU2001281730A1 (en) | 2000-07-26 | 2002-02-05 | Chemometec A/S | Spatially resolved enzyme-linked assay |
| CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US6586524B2 (en) | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| US7141540B2 (en) | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| EP1527176B2 (en) | 2002-08-05 | 2017-03-22 | Silence Therapeutics GmbH | Further novel forms of interfering rna molecules |
| ES2357116T5 (es) * | 2003-06-02 | 2021-09-03 | Univ Massachusetts | Métodos y composiciones para mejorar la eficacia y especificad de FNAi |
| US20050136437A1 (en) | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| WO2005113770A1 (en) * | 2004-05-13 | 2005-12-01 | Institut Gustave Roussy | Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them. |
| EP2230305A1 (en) | 2005-07-21 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Rnai modulation of the rho-a gene and uses thereof |
| US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
| EP1989307B1 (en) | 2006-02-08 | 2012-08-08 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| WO2009044392A2 (en) * | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| WO2009062199A1 (en) | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
| CN102272307A (zh) | 2008-11-21 | 2011-12-07 | 利莱恩斯生命科学有限公司 | siNA介导的VEGF-C和RhoA的敲低对VEGF-A分泌、血管生成和/或新血管生成的抑制 |
| WO2011084193A1 (en) * | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
-
2011
- 2011-06-23 JP JP2013516758A patent/JP5824515B2/ja not_active Expired - Fee Related
- 2011-06-23 KR KR1020137001674A patent/KR101553753B1/ko not_active Expired - Fee Related
- 2011-06-23 US US13/700,942 patent/US9045755B2/en not_active Expired - Fee Related
- 2011-06-23 WO PCT/US2011/041562 patent/WO2011163436A1/en not_active Ceased
- 2011-06-23 EP EP11728750.8A patent/EP2585594B1/en not_active Not-in-force
- 2011-06-23 SG SG2012094652A patent/SG186438A1/en unknown
- 2011-06-23 CN CN201180036371.XA patent/CN103097534B/zh not_active Expired - Fee Related
- 2011-06-23 AU AU2011270896A patent/AU2011270896B9/en not_active Ceased
- 2011-06-23 NZ NZ604094A patent/NZ604094A/en not_active IP Right Cessation
- 2011-06-23 CA CA2801928A patent/CA2801928C/en not_active Expired - Fee Related
- 2011-06-23 RU RU2012153703/10A patent/RU2012153703A/ru not_active Application Discontinuation
-
2012
- 2012-12-12 IL IL223578A patent/IL223578A/en active IP Right Grant
-
2015
- 2015-12-17 US US14/973,388 patent/US20160102313A1/en not_active Abandoned
-
2016
- 2016-08-04 US US15/228,214 patent/US20160333354A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103097534B (zh) | 2017-07-28 |
| CA2801928A1 (en) | 2011-12-29 |
| CN103097534A (zh) | 2013-05-08 |
| SG186438A1 (en) | 2013-01-30 |
| JP5824515B2 (ja) | 2015-11-25 |
| AU2011270896B2 (en) | 2015-04-09 |
| EP2585594B1 (en) | 2017-05-31 |
| US20130137750A1 (en) | 2013-05-30 |
| WO2011163436A1 (en) | 2011-12-29 |
| KR101553753B1 (ko) | 2015-09-16 |
| KR20130028966A (ko) | 2013-03-20 |
| IL223578A (en) | 2017-09-28 |
| EP2585594A1 (en) | 2013-05-01 |
| NZ604094A (en) | 2014-11-28 |
| AU2011270896B9 (en) | 2015-05-07 |
| US20160333354A1 (en) | 2016-11-17 |
| US20160102313A1 (en) | 2016-04-14 |
| AU2011270896A1 (en) | 2013-01-10 |
| CA2801928C (en) | 2018-04-10 |
| US9045755B2 (en) | 2015-06-02 |
| JP2013537404A (ja) | 2013-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012153703A (ru) | Соединения двухцепочечных рнк к rhoa и их применение | |
| ES2560107T3 (es) | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF | |
| RU2014140112A (ru) | Лечение заболеваний, связанных с нейтрофическим фактором головного мозга (bdnf), путем ингибирования природного антисмыслового транскрипта bdnf | |
| RU2011127200A (ru) | Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро | |
| JP2019515688A5 (enExample) | ||
| JP2019511240A5 (enExample) | ||
| JP7379387B2 (ja) | Ａｔｘｎ２発現を制御するためのオリゴヌクレオチド | |
| JP2015511494A5 (enExample) | ||
| RU2015144631A (ru) | Способ получения индуцированных нервных стволовых клеток, перепрограммированных из клеток, не являющихся нервными, с использованием hmga2 | |
| JP2023534557A (ja) | Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド | |
| JP7333079B2 (ja) | 毒性が軽減した核酸 | |
| MX2023003810A (es) | Composiciones de arn de interferencia (arni) de alfa sinucleina (snca) y metodos de usos de las mismas para tratar o prevenir enfermedades neurodegenerativas asociadas con la snca. | |
| CN112218948A (zh) | 防止外显子7和/或外显子8包含到淀粉样前体蛋白(APP)mRNA中 | |
| RU2006129326A (ru) | Ингибиторы передачи сигнала трансформирующих факторов роста (tgf-r) для лечения расстройств цнс | |
| RU2020125769A (ru) | Олигонуклеотиды для модуляции экспрессии tmem106b | |
| US20220220221A1 (en) | Extracellular matrix-producing composition using mast4 gene and preparation method therefor | |
| CN119213125A (zh) | Sarm1 rna干扰试剂 | |
| TW202102676A (zh) | 調節atxn2表現之寡核苷酸 | |
| JPWO2019200129A5 (enExample) | ||
| JP2023513188A (ja) | 遺伝子の発現増加のためのｍｉｒｎａ－４８５阻害剤 | |
| WO2017186815A1 (en) | Antisense oligonucleotides for enhanced expression of frataxin | |
| US20250215436A1 (en) | Antisense Nucleic Acids for Use in the Treatment for KCNQ1 Mutation Carriers | |
| KR101834841B1 (ko) | 줄기세포의 고활성 유도 방법 | |
| Chang et al. | Inhibition of the NGF and IL-1β-induced expression of alzheimer’s amyloid precursor protein by antisense oligonucleotides | |
| WO2002026977A1 (en) | Host cell obtained by transferring vhl gene into cancer cell or embryonic stem cell and expressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160118 |